Table 1.
General characteristics of the included participants.
| 09 Months | 12 Months | 18 Months | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| No booster | 1 booster | 09m - ALL (n40) (N, %) | No booster | 1 booster | 2 boosters | 12m - ALL (n68) (N, %) | No booster | 1 booster | 2 boosters | 18m - ALL (n51) (N, %) | |
|
Age
18-30 31-50 51-62 |
|||||||||||
| 6 7 2 |
5 18 2 |
11 (27.5%) 25 (62.5%) 4 (10%) |
2 16 2 |
6 13 11 |
4 13 1 |
12 (17.6%) 42 (61.8%) 14 (20.6%) |
5 5 1 |
3 16 1 |
4 10 6 |
12 (23.5%) 31 (60.8%) 8 (15.7%) |
|
|
Gender
Male Female |
|||||||||||
| 6 9 |
6 19 |
12 (30%) 28 (70%) |
8 12 |
8 22 |
4 14 |
20 (29.4%) 48 (70.6%) |
4 7 |
1 19 |
6 14 |
11 (21.6%) 40 (78.4%) |
|
|
Comorbiditiesa
Present Absent |
|||||||||||
| 5 10 |
8 17 |
13 (32.5%) 27 (67.5%) |
6 14 |
8 22 |
8 10 |
22 (32.3%) 46 (67.7%) |
3 8 |
4 16 |
9 11 |
16 (31.4%) 35 (68.6%) |
|
|
Prior covid-19 infectionb
Yes No |
|||||||||||
| 0 15 |
2 23 |
2 (5%) 38 (95%) |
2 18 |
2 28 |
0 18 |
4 (5.9%) 64 (94.1%) |
0 11 |
1 19 |
3 17 |
4 (7.8%) 47 (92.2%) |
|
|
Later covid-19 infectionc
Yes No |
|||||||||||
| 6 9 |
10 15 |
16 (40%) 24 (60%) |
8 12 |
8 22 |
13 5 |
29 (42.6%) 39 (57.4%) |
6 5 |
6 14 |
7 13 |
19 (37.3%) 32 (62.7%) |
|
a
Comorbidities: Hypertension; obesity; diabetes; asthma; chronic kidney disease; hypothyroidism; dyslipidemia; chronic rhinitis; chronic sinusitis; rheumatoid arthritis; gastritis; endometriosis; sickle cell anemia.
b
Infection before CoronaVac primary protocol.
c
Infection after CoronaVac primary protocol.